Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
autism spectrum disorders
MedTech
NeuroQure debuts test to ID autism risk at birth
NeuroQure launched a first-of-its-kind test that can identify autism risk at birth, allowing for earlier and more fine-tuned therapies to begin.
Joseph Keenan
Jan 22, 2026 4:50am
LinusBio launches autism diagnostic using single strand of hair
Feb 6, 2025 11:00am
MARAbio’s antibody test for autoimmune-related autism nets $19M
Oct 7, 2024 10:00am
Beyond Air looks beyond lungs to target nitric oxide in autism
Jun 20, 2023 10:54am
Stalicla pledges $270M for Novartis' failed fragile X asset
Jan 9, 2023 8:06am
Gene interaction analysis predicts autism drugs
Sep 12, 2022 7:00pm
